SCHEMBL22137732

SCHEMBL22137732

CCC(CCC(C)(C)C)c1ccc(C)cc1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPA1 O75762 2/20 0.47
▸ LMNA P02545 1/20 0.47
▸ CHRM1 P11229 1/20 0.47
▸ SLC6A2 P23975 1/20 0.47
▸ ADRA1A P35348 1/20 0.47
▸ HTR2B P41595 1/20 0.47
▸ SRC P12931 1/20 0.42
▸ CNR1 P21554 3/20 0.40
▸ CNR2 P34972 3/20 0.40
▸ ALDH1A1 P00352 3/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ IDO1 P14902 1/20 0.35
▸ TDO2 P48775 1/20 0.35
▸ RORC P51449 1/20 0.34
▸ RIPK1 Q13546 2/20 0.33
▸ TP53 P04637 2/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1992208 0.83 TRPA1 (0.61) TRPA1LMNACHRM1SLC6A2ADRA1A
SCHEMBL19578003 0.78 TRPA1 (0.50) TRPA1LMNACHRM1SLC6A2ADRA1A
SCHEMBL9169236 0.72 TRPA1 (0.61) TRPA1LMNACHRM1SLC6A2ADRA1A
SCHEMBL11138508 0.71 LMNA (0.59) TRPA1LMNACHRM1SLC6A2ADRA1A
SCHEMBL4401739 0.71 LMNA (0.64) TRPA1LMNACHRM1SLC6A2ADRA1A
SCHEMBL30893081 0.71 LMNA (0.64) TRPA1LMNACHRM1SLC6A2ADRA1A
SCHEMBL9461044 0.69 LMNA (0.57) TRPA1LMNACHRM1SLC6A2ADRA1A
Potassium SCHEMBL29477939 0.69 LMNA (0.62) TRPA1LMNACHRM1SLC6A2ADRA1A
SCHEMBL29477946 0.69 LMNA (0.62) TRPA1LMNACHRM1SLC6A2ADRA1A
SCHEMBL4595527 0.69 TRPA1 (0.57) TRPA1LMNACHRM1SLC6A2ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020128768-A1 N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE NOVARTIS AG (CH) 2020-06-25 — — WO disclosed
Send feedback